FUJIFILM Corporation to Invest US$200 Million to Expand Global Cell Therapy CDMO Capabilities

Specifications:

Name:

FUJIFILM Corporation to Invest US$200 Million to Expand Global Cell Therapy CDMO Capabilities

Location:

USA

Company:

FUJIFILM Corporation

Estimated Cost:

US$200 Million

Source:

https://fujifilmdiosynth.com/

Introduction:

FUJIFILM Corporation announces the investment of USD 200 million in two subsidiaries to significantly expand global cell therapy contract development and manufacturing (CDMO) capabilities.

Features:

The investment will enable Fujifilm to support the expanding cell therapy market which is anticipated to grow by more than 30% per year up from USD 3.3 billion in FY2022.

The investment will fund FUJIFILM Cellular Dynamics’ new 175,000 sq. ft headquarters in Madison, Wisconsin, U.S.A., located in BioMidwest, a hub of life science companies and academia. The new campus located at 8402 Excelsior Drive will house iPSC cGMP[3] manufacturing with three clean room suites, process development laboratories, warehouse operations and administrative space. This investment will double the Company’s existing manufacturing capacity for the development and commercialization of iPSC-derived cell therapies for its partners. The new site will also include iPSC manufacturing for research and development applications for drug discovery, drug efficacy, and pharmacology. The full site including cell therapy manufacturing will be operational in spring 2026.

The investment in FUJIFILM Diosynth Biotechnologies’ site in Thousand Oaks, California, U.S.A., located near a major cluster of pharmaceutical, biotech, and venture capital firms, will fund the site expansion with a new development lab and two new independent manufacturing clean rooms, significantly increasing production capacity for new client programs. The talent at the California site has strong experience in clinical and commercial manufacturing of in vitro cell lines, targeting a wide variety of cell therapies. The added capacity will be operational in early 2025.